This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specifi c drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specifi c use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
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PATIENT POPULATION
Adult patients with HIV lipodystrophy with trunk enlargement during antiretroviral therapy.
DOSAGE AND DURATION
Recombinant human growth hormone has been administered in several regimens with wide ranges of dosing. Optimal dosing has not been established.
• Initial dose: 2 mcg/kg/day increased to a maximum dose of 6 mcg/kg/day (mean dose, 3.7 mcg/kg/day or 0.33 mg/day) for 18 months 2 • Induction (weeks 1-12): 4 mg daily; maintenance (weeks 12-36): 2 mg every other day 3 • 4 mg daily or every other day for 12 to 24 weeks 4
RESULTS
Recombinant human growth hormone has been studied in controlled and noncontrolled trials enrolling over 500 patients and has demonstrated significant reductions in visceral adipose tissue (VAT) and subcutaneous fat tissue (SAT) but not lean body mass (LBM).
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Systematic Review
A systematic review evaluated the effects growth hormone axis drugs compared to placebo on VAT, SAT, and LBM in patients with HIV-related lipodystrophy. Inclusion criteria involved randomized placebo-controlled trials (RCTs) with patients with HIVrelated lipodystrophy who received growth hormone (GH), growth hormone releasing hormone (GHRH), or tesamorelin or insulin-like growth factor-1 (IGF-1) and assessing at least one primary outcome (eg, VAT, SAT, or LBM). Ten double-blinded RCTs including 1,511 patients were reviewed. The duration of therapy interventions ranged from 12 to 26 weeks, with the majority of studies evaluating growth hormone. ; P < .001) but not LBM (WMD, 1.51 kg; 95% CI, -0.22 to 3.24 kg; P = .09). Overall GH axis drugs signifi cantly increased fasting plasma glucose (WMD, 2.88 mg/dL; 95% CI, 1.10 to 4.65 mg/dL; P = .001), decreasing waist circumference (WMD, -1.61 cm; 95% CI, -2.33 to -0.89 cm; P < .001), decreasing extremity fat (WMD, -0.25 kg; 95% CI, -0.49 to 0.01 kg; P = .04), and decreasing triglycerides (WMD, -25.37 mg/dL; 95% CI, -46.84 to -3.89 mg/dL; P = .02). Although the overall rate of all moderate-tosevere adverse events was not signifi cantly different between GH axis drugs when compared with placebo (relative risk [RR], 1.09; 95% CI, 0.92 to 1.29; P = .32], the number of cases of arthralgia (RR, 1.49; 95% CI, 1.17-1.89; P = .001) and edema (RR, 3.95; 95% CI, 1.73 to 9.00; P = .001) were higher in the GH axis drug arm. 
Controlled Trials
In a double-blind, placebo-controlled trial, 56 HIV patients with abdominal fat accumulation and reduced GH secretion (peak GH < 7.5 ng/mL) were randomly assigned to receive either subcutaneous recombinant growth hormone (r-hGH) or placebo for 18 months. Initial doses were 2 mcg/kg/daily and increased to a maximum of 6 mcg/kg/daily (mean dose, 0.33 mg daily). Primary outcome was change in body fat composition as measured by VAT assessment and change in fat distribution (trunk to extremity fat). A total of 48 patients completed the study. VAT decreased signifi cantly in the r-hGH group compared with placebo (treatment effect, -19 cm 2 ; 95% CI, -38 to -0.5 cm 2 ; P = .049), corresponding to -8.5% and -1.6% changes, respectively. The trunk to lower extremity fat ratio (treatment effect, -0.4; 95% CI, -0.6 to -0.2; P < .001) and trunk fat (treatment effect, -0.8 kg; 95% CI, -1.5 to -0.04 kg; P = .04) decreased in the r-hGH group compared to placebo. Adverse events were not signifi cantly increased in the r-hGH group (23% vs 28%). Triglycerides decreased (treatment effect, 7 mg/dL; P = .002), whereas total cholesterol and high-density lipoprotein cholesterol (HDL-C) were unchanged compared to placebo. 2 In a double-blind, placebo-controlled multicenter trial, 326 patients with HIV-associated adipose redistribution syndrome were randomized to receive r-hGH (4 mg daily) or placebo for 12 weeks. At week 12, patients receiving r-hGH were re-randomized to receive r-hGH (maintenance, 2 mg every other day) or placebo for 24 weeks (to week 36). Patients initially treated with placebo were switched to r-hGH (4 mg daily) at weeks 24 through 36. During the induction period (baseline to week 12), absolute mean changes in intent-to-treat (ITT) population for VAT area were -32.6 cm 2 and 0.5 cm 2 in the r-hGH and placebo groups, respectively. During this period, mean changes were signifi cantly greater in the r-hGH group for abdominal SAT, limb fat, and total fat. Of those who lost VAT during the induction phase (weeks 1-12) and received maintenance dosing, approximately 40.3% gained back greater than 50% of their loss, which was signifi cantly less than those in the placebo group and fi t the criteria for effi cacy in the maintenance phase. Patients in the maintenance group also sustained losses in trunk fat but not losses in subcutaneous fact in the abdomen or limbs. During the induction phase, the patients receiving r-hGH experienced signifi cant mean absolute and percent reductions in total cholesterol, non-HDL-C, and lowdensity lipoprotein cholesterol (LDL-C) and increases in HDL-C and the HDL:LDL ratio. Patients in the placebo group only had signifi cant mean decreases in LDL-C. The authors concluded that patients with HIV-associated adipose redistribution syndrome had greater relative losses of VAT and trunk fat than of subcutaneous fat.
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SAFETY
This is a limited safety profi le. Refer to package labeling for complete prescribing information (eg, Warnings/Precautions, Adverse Reactions, Drug Interactions).
Adverse events attributed to growth hormone in controlled trials have included parasthesias, carpel tunnel syndrome, arthralgias, swelling, hyperglycemia, malignancy, and hypertension, although incidences did not signifi cantly differ from those found with placebo in some studies 2, 3 and were signifi cantly higher in others. 4 
THERAPY CONSIDERATIONS
Recombinant human growth hormone has been studied in controlled and noncontrolled trials, demonstrating signifi cant reductions in VAT, and SAT but not LBM. Dosage regimens vary and optimal dosing has not been established for this indication.
